Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

(2016) P. Jain et al.   BLOOD

Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance

(2015) Gui Xiaomin et al.   LEUKEMIA & LYMPHOMA

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

(2014) B. Hanfstein et al.   HAEMATOLOGICA

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients

(2010) Emad-Aldin I. Osman et al.   GENETICS AND MOLECULAR BIOLOGY

Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions

(2010) Preetha Markose et al.   LEUKEMIA & LYMPHOMA

Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

(2009) A. Pardanani et al.   BLOOD

Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

(2009) D. Verma et al.   BLOOD

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

(2009) C. M. Lucas et al.   HAEMATOLOGICA

A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia

(2009) Natini Jinawath et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD